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Abstract
Background: When conducting a treatment intervention, it is assumed that variability associated with
measurement of the disease can be controlled sufficiently to reasonably assess the outcome. In this study
we investigate the variability of Apnea-Hypopnea Index obtained by polysomnography and by in-home
portable recording in untreated mild to moderate obstructive sleep apnea (OSA) patients at a four- to six-
month interval.
Methods: Thirty-seven adult patients serving as placebo controls underwent a baseline polysomnography
and in-home sleep study followed by a second set of studies under the same conditions. The
polysomnography studies were acquired and scored at three independent American Academy of Sleep
Medicine accredited sleep laboratories. The in-home studies were acquired by the patient and scored using
validated auto-scoring algorithms. The initial in-home study was conducted on average two months prior
to the first polysomnography, the follow-up polysomnography and in-home studies were conducted
approximately five to six months after the initial polysomnography.
Results: When comparing the test-retest Apnea-hypopnea Index (AHI) and apnea index (AI), the in-home
results were more highly correlated (r = 0.65 and 0.68) than the comparable PSG results (r = 0.56 and
0.58). The in-home results provided approximately 50% less test-retest variability than the comparable
polysomnography AHI and AI values. Both the overall polysomnography AHI and AI showed a substantial
bias toward increased severity upon retest (8 and 6 events/hr respectively) while the in-home bias was
essentially zero. The in-home percentage of time supine showed a better correlation compared to
polysomnography (r = 0.72 vs. 0.43). Patients biased toward more time supine during the initial
polysomnography; no trends in time supine for in-home studies were noted.
Conclusion: Night-to-night variability in sleep-disordered breathing can be a confounding factor in
assessing treatment outcomes. The sample size of this study was small given the night-to-night variability
in OSA and limited understanding of polysomnography reliability. We found that in-home studies provided
a repeated measure of sleep disordered breathing less variable then polysomnography. Investigators using
polysomnography to assess treatment outcomes should factor in the increased variability and bias toward
increased AHI values upon retest to ensure the study is adequately powered.
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Obstructive Sleep Apnea (OSA) has recently gained recog-
nition as one of the most common, under-diagnosed
chronic diseases [1,2]. It is characterized by frequent loud
snoring and recurrent failures to breathe adequately dur-
ing sleep (termed apneas or hypopneas), as a result of full
or partial collapse of the upper airway. OSA can be a con-
founding factor in clinical trials because it causes daytime
drowsiness, and has been associated with hypertension,
increased risk of congestive heart failure, coronary artery
disease, myocardial infarction, cardiac arrhythmias, dia-
betes and stroke [3-8].
The most commonly referred prevalence statistic on
obstructive sleep apnea syndrome is that 4% of men and
2% of women have the disease [9]. What doesn't get the
same recognition is that 24% of the men and 9% of the
women in the cohort were found to have sleep disordered
breathing/obstructive sleep apnea (OSA)(i.e., AHI ≥ 5
without daytime somnolence). Because daytime somno-
lence and OSA severity are not well correlated [9,10] and
there are individual differences in susceptibility to sleep
deprivation [11,12], reliance on the former prevalence sta-
tistic could substantially underestimates the degree that
this disease might affect subjects in clinical studies. More
recent reports suggest the prevalence of OSA is increasing
in part due to the rise in obesity, a major risk factor for
OSA. In St. Louis MO, where the obesity rate is 28%, 19%
of an adult surgical population was estimated to have
moderate, severe or very severe OSA [13]. In a recent study
of 331 dental patients, 59% of men and 22% of women
were estimated to have an AHI > 10, and 43% and 12%
were estimated to have an AHI > 20 [14].
In the United States laboratory polysomnography serves
as the gold-standard for evaluating OSA. The PSG is used
to obtain an overall AHI, and this is compared to some
threshold value both for diagnosis and for treatment rec-
ommendations. In treatment outcome studies, however,
the percentage change in AHI is the primary determinant
of success. Thus, the inherent variability associated with
the subject's, conditions, and the measurement tool
become important factors, and it is presumed that the var-
iability can be accurately estimated for purposes of sample
size calculations.
The literature on repeated-measures PSG on symptomatic
patients is somewhat limited. Chediak et al. [15] reported
that 12 of 37 (32%) of their cases exhibited a difference in
AHI ≥ 10 in two sequential nights of PSG. Le Bon et al.
[16] studied 243 subjects during sequential nights of PSG
and evaluated the benefit of improved sensitivity and spe-
cificity as a result of having multiple nights of data. Dean
and Chaudhary [17] investigated PSG variability in nine
patients who appeared negative during the first PSG study
and positive in the second PSG. Carlile and Carlile [18]
found that 48% of patients with an AHI < 5 had AHI val-
ues ≥ 5 on a repeat study.
Most recently Levendowski et al. [19] reported a fairly
weak correlation (r = 0.44) between overall Apnea/
Hypopnea indices from the two PSG studies conducted
approximately 40 days apart with a 7 event/hour bias
toward increasing AHI values upon retest.
The goal of this study was to assess the test – retest varia-
bility in untreated mild to moderate OSA patients studied
with both a laboratory PSG and an in-home recording
with a substantial time between the test and retest.
Methods
The data were obtained from a multi-site, double blind
placebo controlled study whose aim was to assess the effi-
cacy of palatal implants as a treatment for mild to moder-
ate OSA. Exclusion criteria were an AHI < 10 or > 40 based
on the in-home baseline study, body mass index > 32 kg/
m2, evidence of airway obstruction other than retro-pala-
tal, prior airway surgery other than nasal, adenoid or ton-
sil, and presence of another sleep disorder (restless legs,
insomnia, narcolepsy, etc.)
Thirty-seven patients from the placebo group underwent a
baseline PSG and in-home sleep study followed by a sec-
ond set of studies under the same conditions. The in-
home studies were conducted approximately 60 days
prior to the initial PSG studies (mean 59 ± 34 days). The
time between the test and retest for PSG was almost five
months (mean 140 + 35 days) and for the in-home stud-
ies was over six months (mean 188 + 47 days). The follow-
up PSG and in-home studies were typically conducted
within three weeks (mean 18 ± 21 days). Each subject had
his or her test and retest PSG done at the same accredited
sleep disorders center, with 12 subjects studied at the Uni-
versity of Cincinnati, 13 studied at the Medical College of
Wisconsin, and 12 studied at Total Sleep Diagnostics of
Indianapolis. The PSG data were acquired and scored by
registered polysomnographic technicians applying the
pre-2007 American Academy of Sleep Medicine guideline
to classify apneas (i.e., 10-second cessation in airflow)
and hypopneas (i.e., > 30% decrease in airflow and > 3%
desaturation), and sleep staging (i.e., Rechtschaffen and
Kales criteria) across sites. Total sleep times were 308 ± 61
SD minutes during the PSG test and 323 ± 50 SD minutes
during the PSG retest.
The in-home studies were performed with Apnea Risk
Evaluation System (ARES™) Unicorder (Advanced Brain
Monitoring, Carlsbad, CA, USA). The ARES Unicorder
measures oxygen saturation, pulse rate, airflow, respira-
tory effort, snoring levels, head movement, and head posi-Page 2 of 8
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strap to the forehead. Reflectance oximetry is used to
obtain the SpO2 and pulse rate signals. Respiratory effort
is derived from the measurement of changes in forehead
venous pressure acquired using a combination of photop-
lethysmography and changes in surface pressure of the
reflectance oximetry sensor, and head movement. Airflow
is obtained via a nasal cannula and a pressure transducer.
A calibrated acoustic microphone is used to acquire quan-
tified snoring levels (dB). Accelerometers are used to
measure head movement and derive head position. The
recorder was designed to be easily affixed by the patient,
and provide alerts during the study if poor quality airflow
or SpO2 is detected so the device could be adjusted.
Automated scoring algorithms were applied off-line to
detect sleep disordered breathing. The AHI was computed
using a time-in-bed measure based on recording time with
acceptable signal quality minus periods when the patient
was upright or presumed to be awake based on actigraphy.
Apneas, based on a 10-s cessation of airflow detected by
the automated algorithms and hypopnea events that met
the Medicare criteria required a 50% reduction and recov-
ery in airflow, and a minimum 3.5% reduction in SpO2
and at least a 1.0% recovery were included in the apnea-
hypopnea index (AHI-4%). Fifteen of the patients
recorded two nights of in-home data during the test, two
subjects completed a multi-night study during the retest.
The total and valid recording times for the initial in-home
test were 500 ± 211 and 451 ± 160 minutes respectively,
and 406 ± 106 and 365 ± 104 minutes for the in-home
retest.
Pearson correlations and Bland-Altman plots were used to
assess the association in sleep disordered breathing
between the test vs. retest data. Differences between the
test and retest in demographic data and sleep parameters
were tested with Student paired t-test.
Results
Correlation and Bland-Altman plots between the test and
retest data for the PSG and in-home studies (HST) are pre-
sented in Figures 1, 2, 3 and 4 for the overall AHI and
apnea index. The in-home data consistently provided
higher correlations and approximately 50% less variance
than the PSG results. More importantly, the PSG data were
biased toward higher AHI and apnea index values at retest
while the in-home data were not. This trend toward
reduced variability in the home recordings applied to the
supine AHI data as well (Figures 5 and 6). The percentage
of time supine was substantially more consistent when
measured in the home (Figure 7). There was a bias toward
increased time supine during the PSG-test vs. the PSG-
retest (bias 12 ± 22%) while the in-home bias in the per-
centage time supine was neutral (bias 0 ± 16%). There
were no changes in the subject's BMI and neck size
between the test and retest. Bland-Altman plots revealed a
slight bias toward a greater AHI values detected by the ini-
tial in-home sleep study as compared to the initial PSG
study (Bias 1.8 ± 11 SD events/hour). When comparing
the retest results, the PSG showing a bias toward greater
AHI values vs. the in-home studies (Bias 5.6 ± 27 SD
events/hour).
Table 1 shows the sample size required to obtain two
standard levels of statistical power for treatment studies in
which the desired outcome is a 50% reduction in AHI.
Correlations of test-retest AHI values for: a) PSG and b) HSTFigure 1
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respective inter-class correlation values observed for each
measure. The "No bias" rows consider that it is impossible
to know the expected value of the change over time; it may
be that it really is the case that subjects' conditions wors-
ened as the PSG indicates and, hence the in-home results
are positively biased for treatment effects (rather than the
other way around). Thus these rows assume the statistical
test would be purely a change score test against an unan-
chored, and not clinically meaningful, value. The
observed bias rows incorporate the results presented in
Figure 2 in which the PSG is biased in the opposite direc-
tion of a positive treatment effect. One would therefore
need additional treatment effect to overcome the meas-
urement bias to achieve an observed treatment effect that
meets the gold standard of 50% reduction.
Discussion
This is the first study which compares AHI variability in
untreated mild to moderate OSA patients studied with
PSG and in-home with a substantial time between the test
and retest (i.e., five to six months). When comparing the
overall AHI and apnea index values, the in-home results
provided approximately 50% less variability than the PSG
Bland-Altman plots of test-retest AHI values for: a) PSG and b) HSTFigure 2











0 10 20 30 40 50 60 70



























0 10 20 30 40 50 60 70


















Bias:  -8 + Bias:  0 + 11 SD  16 SD 
Correlations of test-retest apnea index values for: a) PSG and b) HSTFigure 3
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of the PSG bias and variability came from the six subjects
whose PSG-AHI had increased by more than 30 between
the test and retest. By way of comparison, the ARES AHI
increased by more than 20 in two of these six subjects, in
one case it decreased by 21, and the change was less than
5 events/hr in the remaining three. If the six subjects
(17%) are excluded from the analyses, the results from the
two methods become quite similar (ARES AHI: bias = 0.6,
SD = 8.5; PSG AHI: bias = -0.7, SD = 8.6). Neither the
demographic data nor the sleep parameters (TST, % time
supine) supported these six subjects being dropped as
their results did not differ significantly with the rest of the
cohort (all p > 0.1). At best, the variability might be
explained by a first-night effect for PSG that is known to
under-report the severity of the disease in OSA subjects
[17-19].
The substantially lower apnea and hypopnea variability
obtained with the in-home system was likely influenced
by the use of the same equipment and auto-scoring algo-
rithms. The in-home device and auto-scoring algorithms
used in this study was described and validated in two pre-
vious studies. The first had 284 valid comparisons of the
Bland-Altman plots of test-retest apnea index values for: a) PSG and b) HSTFigure 4












0 10 20 30 40 50 60 70



























0 10 20 30 40 50 60


















Bias:  -6 + 16 SD 
Bias:  0 + 9 SD 
Correlations of test-retest Supine AHI values for: a) PSG and b) HSTFigure 5







0 20 40 60 80 100 120
















0 20 40 60 80 100 120














r = 0.60, p<0.0001 r = 0.51, p=0.001 Page 5 of 8
(page number not for citation purposes)
International Archives of Medicine 2009, 2:2 http://www.intarchmed.com/content/2/1/2in-laboratory simultaneous PSG and ARES and 187 valid
comparisons of the in-laboratory PSG with a separate two
nights unattended self-applied ARES Unicorder [20]. The
second study with 102 participants had 92 simultaneous
in-laboratory comparisons and 86 in-home to in lab com-
parisons [21]. Both studies showed that the ARES had
high sensitivity and specificity. It is uncertain whether the
findings in this study apply to other in-home Level III
sleep study devices.
A limitation of this study is that the conditions used to
acquire the PSG data reflect the conventional practice at
sleep centers, as opposed to employing extra-ordinary
means to control variability. For example, it was previ-
ously reported that the depth of desaturation varies by
equipment manufacturer [22] and the AHI used in this
study was based on a 4% desaturation. However we could
not ensure the same type of pulse-oximeter was used in all
rooms and at all sites. Although the procedures used to
score the sleep and respiratory events within and across
the sleep centers were standardized, intra- and inter-rater
reliability assessments were not made. We found no statis-
tically significant differences in test-retest reliability
among the three sleep centers. There was, however, a
Bland-Altman plots of test-retest Supine AHI values for: a) PSG and b) HSTFigure 6
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results even though all three centers followed identical
guidelines for data acquisition and scoring. This finding
suggested that future multi-site PSG-based outcome stud-
ies should consider utilizing a single facility for the scor-
ing of the data to improve test-retest reliability. Of
interest, the overall AHI scored by multiple technicians in
this study showed improved correlations as compared to
a previous report in which a single technician scored all
the records (r = 0.56 vs. 0.44) [19].
Another factor which may have impacted reliability for
both the in-home and PSG studies was the selection of
patients with AHI values between 10 and 40 based on the
initial in-home study. Previous reports suggest that
patients with mild to moderate OSA tend to have posi-
tional dependent severity that is more readily influenced
by the time spent in the supine position.
Differences in the supine AHI variability were less severe
with the ARES studies as compared to PSG may be
explained by the percentage of time supine being more
consistent in-home vs. in-lab. The correlations in the per-
cent time supine for the in-home study in this group (r =
0.72) studied approximately five months apart was very
similar to the results from a group studied under similar
circumstances 40 days apart (r = 0.70) [18]. Patients spent
less time supine in the lab during their retest, thus the
expected impact of gravity on AHI does explain the bias
toward increased PSG-AHI values upon retest. The in-
home study recorded head position while the PSG studies
used chest position, but it's uncertain what role this
played in the supine positional results.
Several of the factors that might have impacted the test vs.
retest AHI values were controlled by comparing labora-
tory and in-home results obtained under relatively similar
circumstances. The subjects represented a homogenous
group of subjects with baseline AHI values in the mild to
moderate range, not excessively obese and without other
sleep disorders. Although the initial in-home study was
conducted two months earlier than the initial PSG study,
the weight, BMI and neck circumference of the subjects
did not significantly change between any of the in-home
and PSG studies (all t-test p > 0.1). If a patient changed
medication between the test and retest, it should have
impacted both the PSG and in-home data similarly. In a
previous study, Levendowski et al [19] was unable to
relate differences in sleep architecture with differences in
repeated measure PSG-AHI values. This study points
toward a need for a well controlled prospective study to
further clarify the issues which impact PSG variability.
The results from this study suggest major ramifications for
the planning of future treatment studies. If one assumes
no bias, and incorporates the observed reliability for the
respective measures, the sample size required for PSG
would be approximately three times that required for an
ARES in-home study. Assuming the PSG is biased toward
increasing values upon retest, the sample size required is
more than 2 orders of magnitude larger than for the ARES
and effectively impossible to implement. The bias toward
increasing AHI values upon retest by PSG in this study
(7.7 events/hour, p < .01) is very similar to the results
reported by Levendowski et al. (i.e., 7 event/hour increase
in PSG-AHI values at a 40 day retest) [19] and it is unlikely
a coincidence. Other studies have also reported a "first-
night" effect whereby PSG AHI values increase at retest
[17,18].
Conclusion
Test-retest variability in the sleep disordered breathing
severity can be a confounding factor in assessing treat-
ment outcomes. These data suggest that in-home studies
provide a repeated measure of sleep disordered breathing
less variable that that obtained by PSG at multiple sites.
Guidelines developed to standardize the scoring of sleep
and detection of related events (i.e., accreditation by the
American Academy of Sleep Medicine) appears ineffective
in controlling the inherent variability of OSA when meas-
ured by PSG. The acquisition of multi-night PSG studies is
both difficult for subjects and very expensive. Investiga-
tors using PSG for assessing treatment outcomes should
factor in the increased variability and tendency toward
increased AHI values upon retest when selecting a sample
size to ensure the study is adequately powered.
Table 1: Sample sizes required to provide nominal statistical power for 50% treatment effect within subject.
ARES PSG
Assumption 1-β = .80 1-β = .90 1-β = .80 1-β = .90
No bias, no reliability 24 31 57 76
No bias, observed reliability 10 13 27 35
Observed bias, no reliability 26 34 3,499 4,684
Observed bias, observed reliability 11 14 1,541 2,062
Assumed α = .05 *Nearest whole number sample size to generate, at minimum, the nominal value.Page 7 of 8
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AHI: apnea/hypopnea index; PSG: polysomnography;
OSA: obstructive sleep apnea; AI: apnea index; ARES:
Apnea Risk Evaluation System
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